Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO

Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference

Multi-franchise strategy ongoing in depression, neurology and neuropsychiatry

Commercial infrastructure build completed for ZULRESSO (brexanolone) injection ahead of March 19, 2019 target PDUFA date

Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum depression

First patient dosed in second pivotal trial of SAGE-217 in major depressive disorder

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer,... More

Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression

Statistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD)

Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient... More